- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01947517
The Retention Rate Between Brand A and Brand B Punctal Plugs
March 30, 2017 updated by: Dr. Stephanie Baxter, Queen's University
The Retention Rate Between Superflex Punctal Plugs, and Parasol Punctal Occluders
The purpose of this study is to determine if Parasol punctal occluders (Brand A) have a higher rate of retention than Superflex punctal plugs (Brand B).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Eyes will be randomized to either Brand A or Brand B punctal plug.
The primary outcome measure is length of time punctual plugs are retained, measured in months.
This will be measured at monthly assessments for 6 months.
Secondary outcome measures include patient satisfaction, and improvement in subjective and objective dry eye scores, as well as complications related to punctual plugs including spontaneous plug loss, and intolerance.
We will evaluate these measures by repeating the Canadian Dry Eye Assessment, Schirmer 1, tear meniscus height, fluorescein corneal staining (NEI scale), and lissamine green conjunctival staining (NEI scale) at month 1, month 3, and month 6 visits.
Study Type
Observational
Enrollment (Actual)
52
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 5G2
- Department of Ophthalmology, Hotel Dieu Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients will be recruited from cornea and general ophthalmology specialist practices at Hotel Dieu Hospital, Queens University
Description
Inclusion Criteria:
- moderate dry eye, severe dry eye
Exclusion Criteria:
- silicone allergy, punctal stenosis, punctal occlusion, punctal cautery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Parasol Punctal Occluder Group
Randomized to receive Brand A punctal plugs
|
Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
|
Superflex Punctal Occluder Group
Randomized to receive Group B punctal plugs
|
Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Length of Retention
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Canadian Dry Eye Assessment Score
Time Frame: 6 months
|
Describes the scores on a scale and range from 0-3.
Higher score represents more severe dry eye.
Score 0 = no dry eye symptoms, score 1 = mild dry eye symptoms, score 2 = moderate dry eye symptoms, score 3 = severe dry eye symptoms.
|
6 months
|
National Eye Institute Corneal Fluorescein Staining Pattern
Time Frame: 6 months
|
The cornea is divided into 5 zones, and the inferior zone 5 was assessed for staining pattern.
Grade 0= no staining, grade 1= trace staining, grade 2= mild staining, grade 3= moderate staining, and grade 4= severe staining.
|
6 months
|
National Eye Institute Grading for Conjunctival Staining
Time Frame: 6 months
|
The conjunctival staining is divided into 6 zones.
Each zone received a score for staining with lissamine green.
Grade 0= no staining, grade 1= trace staining, grade 2= mild staining, grade 3= moderate staining, grade 4= severe staining.
Data from different zones was combined and the total value was averaged.
|
6 months
|
Tear Meniscus Height
Time Frame: 6 months
|
Meniscus height measured in mm
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ashley R Brissette, BSc, MD, Queens University
- Principal Investigator: Stephanie Baxter, MD, FRCSC, Queens University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
August 1, 2014
Study Registration Dates
First Submitted
September 17, 2013
First Submitted That Met QC Criteria
September 17, 2013
First Posted (Estimate)
September 20, 2013
Study Record Updates
Last Update Posted (Actual)
June 16, 2017
Last Update Submitted That Met QC Criteria
March 30, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Punctal plugs
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Singapore National Eye CentreCompleted
Clinical Trials on Parasol Punctal Occluder
-
Lahey ClinicCompletedDry Eye SyndromeUnited States
-
Mati Therapeutics Inc.CompletedDry Eye SyndromesUnited States
-
AllerganCompleted
-
China National Center for Cardiovascular DiseasesRecruiting
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruitingMigraine | Migraine Headache | PFO - Patent Foramen Ovale | Migraine Headache, With or Without AuraChina
-
Abbott Medical DevicesTerminatedAtrial Septal Defect SecundumUnited States
-
Tanta UniversityCompleted
-
Occlutech International ABActive, not recruitingStroke | PFO - Patent Foramen OvaleFrance, Germany, Italy, Canada
-
Abbott Medical DevicesActive, not recruitingVentricular Septal DefectsUnited States, Canada